📋 The Bigger Regulatory Picture
The digital platform is part of a broader effort by India’s drug regulator to modernise its approach. In 2026, the CDSCO has also been moving toward a risk-based inspection model — prioritising high-risk facilities for more frequent scrutiny while reducing routine burdens on well-established, compliant manufacturers. The DCGI has also overseen new export norms introduced in mid-2026 that tighten checks on unapproved medicines and strengthen export documentation requirements.
Together, these changes signal a regulator that is investing in both technology and risk-proportionate enforcement — a direction that should, over time, make it easier for genuine buyers to distinguish compliant manufacturers from the rest.
📌 Where to Find Verified Distributors
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA member distributors are vetted and can provide current WHO-GMP certificates, CDSCO manufacturing licences, and product-specific approvals on request.
For more information, contact IMSDA at contact@indiamedicine.org.
⚠️ What Buyers Should Do Now
The platform is not yet live. Until it is fully operational, buyers should continue using existing verification practices and prepare for the transition:
- Collect certificate numbers now — ask every supplier for the full certificate number, issuing body, issue date, and expiry date. This information will be essential when digital verification becomes available.
- Verify the manufacturing site address — ensure the WHO-GMP or CDSCO certificate explicitly names the facility that actually produces the product, not just the corporate headquarters.
- Ask for re-verification commitments — when negotiating long-term supply contracts, ask suppliers whether they can re-verify credentials through the CDSCO platform once it goes live.
- Build a compliance file — keep a dated record of every certificate, licence, and product approval for each supplier and product, updated at least annually.
- Monitor CDSCO announcements — the DCGI has indicated the platform will roll out in phases. Buyers should track official CDSCO communications and industry press for go-live dates and public-access details.
📋 The Bigger Regulatory Picture
The digital platform is part of a broader effort by India’s drug regulator to modernise its approach. In 2026, the CDSCO has also been moving toward a risk-based inspection model — prioritising high-risk facilities for more frequent scrutiny while reducing routine burdens on well-established, compliant manufacturers. The DCGI has also overseen new export norms introduced in mid-2026 that tighten checks on unapproved medicines and strengthen export documentation requirements.
Together, these changes signal a regulator that is investing in both technology and risk-proportionate enforcement — a direction that should, over time, make it easier for genuine buyers to distinguish compliant manufacturers from the rest.
📌 Where to Find Verified Distributors
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA member distributors are vetted and can provide current WHO-GMP certificates, CDSCO manufacturing licences, and product-specific approvals on request.
For more information, contact IMSDA at contact@indiamedicine.org.
🔍 Why This Matters for International Buyers
For hospitals, government procurement agencies, retail pharmacies, and distributors sourcing generic medicines from India, the digital platform promises several practical improvements:
- Faster verification of manufacturer credentials — digital certificates with unique identifiers can be checked against a central registry rather than relying on PDF copies supplied by the seller.
- Clearer inspection history — buyers may eventually be able to see whether a manufacturing site has recent, clean inspection records before placing a bulk order.
- Reduced documentation fraud — a centralised digital record makes it harder for bad actors to present expired, counterfeit, or facility-mismatched certificates.
- Better alignment with international requirements — digitised records are easier to share with destination-country regulators, potentially smoothing import clearance.
⚠️ What Buyers Should Do Now
The platform is not yet live. Until it is fully operational, buyers should continue using existing verification practices and prepare for the transition:
- Collect certificate numbers now — ask every supplier for the full certificate number, issuing body, issue date, and expiry date. This information will be essential when digital verification becomes available.
- Verify the manufacturing site address — ensure the WHO-GMP or CDSCO certificate explicitly names the facility that actually produces the product, not just the corporate headquarters.
- Ask for re-verification commitments — when negotiating long-term supply contracts, ask suppliers whether they can re-verify credentials through the CDSCO platform once it goes live.
- Build a compliance file — keep a dated record of every certificate, licence, and product approval for each supplier and product, updated at least annually.
- Monitor CDSCO announcements — the DCGI has indicated the platform will roll out in phases. Buyers should track official CDSCO communications and industry press for go-live dates and public-access details.
📋 The Bigger Regulatory Picture
The digital platform is part of a broader effort by India’s drug regulator to modernise its approach. In 2026, the CDSCO has also been moving toward a risk-based inspection model — prioritising high-risk facilities for more frequent scrutiny while reducing routine burdens on well-established, compliant manufacturers. The DCGI has also overseen new export norms introduced in mid-2026 that tighten checks on unapproved medicines and strengthen export documentation requirements.
Together, these changes signal a regulator that is investing in both technology and risk-proportionate enforcement — a direction that should, over time, make it easier for genuine buyers to distinguish compliant manufacturers from the rest.
📌 Where to Find Verified Distributors
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA member distributors are vetted and can provide current WHO-GMP certificates, CDSCO manufacturing licences, and product-specific approvals on request.
For more information, contact IMSDA at contact@indiamedicine.org.
📋 What the CDSCO Digital Platform Covers
According to the DCGI’s announcement at iPHEX 2026 (September 2026) and subsequent reporting by Pharmabiz.com (August 3, 2026), the platform will cover multiple stages of the drug regulatory lifecycle:
- Online application portal for new drug approvals, manufacturing licences, and import licences — reducing paper-based submissions and manual processing.
- Digital inspection scheduling and tracking — regulators and manufacturers can track inspection dates, findings, and corrective-action status online.
- E-certification — WHO-GMP and other GMP certificates issued and verifiable digitally, reducing the risk of forged or outdated certificate submissions.
- Public-facing transparency — the DCGI has referenced making regulatory status and inspection history more accessible, though the exact scope of public-facing tools has not been fully detailed.
🔍 Why This Matters for International Buyers
For hospitals, government procurement agencies, retail pharmacies, and distributors sourcing generic medicines from India, the digital platform promises several practical improvements:
- Faster verification of manufacturer credentials — digital certificates with unique identifiers can be checked against a central registry rather than relying on PDF copies supplied by the seller.
- Clearer inspection history — buyers may eventually be able to see whether a manufacturing site has recent, clean inspection records before placing a bulk order.
- Reduced documentation fraud — a centralised digital record makes it harder for bad actors to present expired, counterfeit, or facility-mismatched certificates.
- Better alignment with international requirements — digitised records are easier to share with destination-country regulators, potentially smoothing import clearance.
⚠️ What Buyers Should Do Now
The platform is not yet live. Until it is fully operational, buyers should continue using existing verification practices and prepare for the transition:
- Collect certificate numbers now — ask every supplier for the full certificate number, issuing body, issue date, and expiry date. This information will be essential when digital verification becomes available.
- Verify the manufacturing site address — ensure the WHO-GMP or CDSCO certificate explicitly names the facility that actually produces the product, not just the corporate headquarters.
- Ask for re-verification commitments — when negotiating long-term supply contracts, ask suppliers whether they can re-verify credentials through the CDSCO platform once it goes live.
- Build a compliance file — keep a dated record of every certificate, licence, and product approval for each supplier and product, updated at least annually.
- Monitor CDSCO announcements — the DCGI has indicated the platform will roll out in phases. Buyers should track official CDSCO communications and industry press for go-live dates and public-access details.
📋 The Bigger Regulatory Picture
The digital platform is part of a broader effort by India’s drug regulator to modernise its approach. In 2026, the CDSCO has also been moving toward a risk-based inspection model — prioritising high-risk facilities for more frequent scrutiny while reducing routine burdens on well-established, compliant manufacturers. The DCGI has also overseen new export norms introduced in mid-2026 that tighten checks on unapproved medicines and strengthen export documentation requirements.
Together, these changes signal a regulator that is investing in both technology and risk-proportionate enforcement — a direction that should, over time, make it easier for genuine buyers to distinguish compliant manufacturers from the rest.
📌 Where to Find Verified Distributors
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA member distributors are vetted and can provide current WHO-GMP certificates, CDSCO manufacturing licences, and product-specific approvals on request.
For more information, contact IMSDA at contact@indiamedicine.org.
India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), is building an end-to-end digital drug regulatory platform that the Drug Controller General of India (DCGI) expects to launch in phases within 18 months. The system is designed to digitise everything from drug approval applications to inspection tracking and certificate issuance — and it has direct implications for international buyers of Indian generic medicines.
📋 What the CDSCO Digital Platform Covers
According to the DCGI’s announcement at iPHEX 2026 (September 2026) and subsequent reporting by Pharmabiz.com (August 3, 2026), the platform will cover multiple stages of the drug regulatory lifecycle:
- Online application portal for new drug approvals, manufacturing licences, and import licences — reducing paper-based submissions and manual processing.
- Digital inspection scheduling and tracking — regulators and manufacturers can track inspection dates, findings, and corrective-action status online.
- E-certification — WHO-GMP and other GMP certificates issued and verifiable digitally, reducing the risk of forged or outdated certificate submissions.
- Public-facing transparency — the DCGI has referenced making regulatory status and inspection history more accessible, though the exact scope of public-facing tools has not been fully detailed.
🔍 Why This Matters for International Buyers
For hospitals, government procurement agencies, retail pharmacies, and distributors sourcing generic medicines from India, the digital platform promises several practical improvements:
- Faster verification of manufacturer credentials — digital certificates with unique identifiers can be checked against a central registry rather than relying on PDF copies supplied by the seller.
- Clearer inspection history — buyers may eventually be able to see whether a manufacturing site has recent, clean inspection records before placing a bulk order.
- Reduced documentation fraud — a centralised digital record makes it harder for bad actors to present expired, counterfeit, or facility-mismatched certificates.
- Better alignment with international requirements — digitised records are easier to share with destination-country regulators, potentially smoothing import clearance.
⚠️ What Buyers Should Do Now
The platform is not yet live. Until it is fully operational, buyers should continue using existing verification practices and prepare for the transition:
- Collect certificate numbers now — ask every supplier for the full certificate number, issuing body, issue date, and expiry date. This information will be essential when digital verification becomes available.
- Verify the manufacturing site address — ensure the WHO-GMP or CDSCO certificate explicitly names the facility that actually produces the product, not just the corporate headquarters.
- Ask for re-verification commitments — when negotiating long-term supply contracts, ask suppliers whether they can re-verify credentials through the CDSCO platform once it goes live.
- Build a compliance file — keep a dated record of every certificate, licence, and product approval for each supplier and product, updated at least annually.
- Monitor CDSCO announcements — the DCGI has indicated the platform will roll out in phases. Buyers should track official CDSCO communications and industry press for go-live dates and public-access details.
📋 The Bigger Regulatory Picture
The digital platform is part of a broader effort by India’s drug regulator to modernise its approach. In 2026, the CDSCO has also been moving toward a risk-based inspection model — prioritising high-risk facilities for more frequent scrutiny while reducing routine burdens on well-established, compliant manufacturers. The DCGI has also overseen new export norms introduced in mid-2026 that tighten checks on unapproved medicines and strengthen export documentation requirements.
Together, these changes signal a regulator that is investing in both technology and risk-proportionate enforcement — a direction that should, over time, make it easier for genuine buyers to distinguish compliant manufacturers from the rest.
📌 Where to Find Verified Distributors
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA member distributors are vetted and can provide current WHO-GMP certificates, CDSCO manufacturing licences, and product-specific approvals on request.
For more information, contact IMSDA at contact@indiamedicine.org.